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OPTIMIZATION OF THE CONDITIONS NECESSARY TO SHOW BINDING 
OF THE PLASMODIUM YOELII RHOP-3 RHOPTRY PROTEIN TO MOUSE 
ERYTHROCYTES 
 
LATOYA T. MYRIE 
 
ABSTRACT 
 
 
The Plasmodium Rhop-3 rhoptry protein is an erythrocyte binding protein that is secreted 
into the RBC membrane during merozoite invasion.  Anti-Rhop-3 antibodies inhibit 
merozoite RBC invasion.   The C-terminus of the Rhop-3 protein is highly conserved 
among Plasmodium species and antisera from endemic areas reacts with recombinant C-
terminus of Rhop-3.  The binding domain of the Rhop-3 protein is hypothesized to be 
within the C-terminal region of the protein.   
       In the present study I investigated the conditions necessary for binding of the Rhop-3 
protein to RBC by expressing recombinant proteins made from partial fragments of the 
Rhop-3 gene using the vector pDisplayTM.  Recombinants were constructed, purified and 
used to transfect mammalian COS-7 cells.  Surface expression of the proteins was 
detected by immunofluorescence assay (IFA) using Rhop-3 specific antibodies.  A 
rosetting assay was used to determine whether uninfected mouse red blood cells would 
bind to COS-7 cells expressing Rhop-3 recombinant proteins on the surface. 
       The pDisplayTM vector was used to express three Plasmodium falciparum Rhop-3 
recombinants pDIS-PF17, pDIS-PF13, pDIS-PF7 and one P. yoelii Rhop-3 recombinant 
pDIS-PY1412 in COS-7 cells.  Surface expression of recombinant Rhop-3 on COS-7 
cells was identified using three mouse antibodies (MAb) F1, MAb FL1+FL2, MAb T1 
iv 
 
and rabbit antibody # 686. Expression of the recombinant Rhop-3 recombinant pDIS-
PY1412 remained consistent.   
     Binding the recombinant Rhop-3 recombinant pDIS-PY1412 to mouse RBC was 
obtained once but this binding was not consistent. 
      The conditions used for the transfection and binding assays were modified to see if 
consistent binding with pDIS-PY1412 could be maintained.  This is the first time the 
pDisplayTM vector has been used to study Plasmodium yoelii erythrocyte binding 
proteins.  Expression of the PvDBPII control remained consistent and binding to human 
duffy positive RBC was also consistent. Optimizing the conditions for binding of pDIS-
PY1412 to mouse RBC would be an essential tool to screen other Plasmodium yoelii 
RBC binding proteins. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1 Epidemiology 
 
     Malaria is a disease affecting 300-500 million people annually resulting in 2-3 
million deaths per year [Ashley et al. 2006]. Pregnant women and children have an 
increased susceptibility to malaria [Ashley et al. 2006] with mortality predominant in 
children.  According to the United States Centers for Disease Control and Prevention 
an estimated 75,000-200,000 infants die from malaria associated infections during 
pregnancy.    
     Malaria is prevalent in areas of sub-Saharan Africa with nearly 30% of the 
mortality rate being attributed to malaria [Snow et al. 2001]. Malaria is also 
transmitted in large areas of Central and South America, the island of Hispaniola, 
Asia (including areas of India, Indonesia, Iran, Iraq, Sri Lanka, Philippines, Pakistan), 
Eastern Europe and the South Pacific [Leder et al. 2004] [Fig 1]. Malaria is caused by 
protozoans of Plasmodium spp. There are four Plasmodium spp. which infect 
humans, P. vivax, P. falciparum, P. ovale and P. malariae. Plasmodium falciparum is 
the most lethal of the Plasmodium sp. in humans. Malaria continues to be a major 
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public health problem in Africa, Asia and Latin America due to increased resistance 
of the malaria parasites to antimalarial drugs such as chloroquine and primaquine.              
The distribution of Plasmodium species varies among the different countries. 
Plasmodium falciparum is the predominant species in malaria endemic regions giving 
rise to the drug resistant strains [Gaye et al.1998]. Climatic factors influence the 
distribution of malaria. Areas with increased rainfall provide an environmental 
condition, which promotes mosquito breeding [Grover-Kopec et al. 2006]. Regions 
with increased temperatures are also important in regulation of the development of 
mosquito larvae and adult mosquito survival. The parasite multiplies faster at higher 
temperatures and the mosquitoes also develop faster at these high temperatures 
[Grover-Kopec et al. 2006].  
     Plasmodium falciparum accounts for about 80% of malaria cases in Sub-Saharan 
Africa [Lim et al. 2005]. Plasmodium vivax is the most common of the malaria 
species responsible for 70-80 million cases of malaria annually worldwide [Mendis et 
al. 2001]. Plasmodium vivax is predominantly found in the Middle East, Asia and the 
Western pacific but is not as common in the sub-Saharan Africa. Plasmodium vivax 
represents approximately 10 % of the malaria cases in Africa and over half of the 
malaria cases worldwide [Mendis et al. 2001]. Plasmodium malariae is common in 
many regions of tropical Africa, Sri Lanka, New Guinea, Malaya, Europe and also 
regions of South America [Schmidt et al. 2000]. Plasmodium ovale is the rarest of the 
human malarial parasites. Plasmodium ovale is found mainly in the tropics most 
commonly on the West Coast of Africa, India, New Guinea, Vietnam and the 
Philippines [Schmidt et al. 2000]. 
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Fig1. Malaria endemic regions of the world                                                          
[http://newsimg.bbc.co.uk/media/images/39715000/gif/_39715741_world_malaria_m
ap416.gif] 
 
     Other Plasmodium species also infect other animals such as birds, reptiles and 
rodents (Table1). The genus Plasmodium is divided into thirteen subgenera, three of 
which occurs in mammals, four in birds and two in lizards [Garnham 1966]. Malaria 
parasites belonging to the subgenera Vinckeia and Laverania occur exclusively in 
mammals. Plasmodium falciparum belongs to the subgenera Laverania which occurs 
in primates. Malaria parasites affecting rodents belong to the subgenera Vinckeia. The 
avian malarial parasites belong to the subgenera Haemoamoeba, Giovannolaia, 
Novyella and Huffia [Garnham 1966]. The pathology in birds is associated with 
exoerythrocytic schizogony in the capillary endothelium of different organs 
especially in the brain [Garnham 1966]. Parasite growth in the endothelium results in 
blockage of vessels and results in birds dying of ‘cerebral malaria’. The parasite can 
also attack the bone marrow causing the bird to die of aplastic anemia [Garnham 
1966]. Whereas, in primates the tissue stages of infection are not harmful. In birds 
schizonts can also be released in the internal organs such as the heart muscle leading 
to death. The level of infectivity in birds is influenced by the different subgenera to 
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which the parasite belongs. Avian malaria has a wider host range compared to 
mammalian malaria and is also found in more countries of the world [Garnham 
1966]. The fact that birds have the ability to migrate from one region to another has 
made it possible for avian malaria to be found in every continent of the world 
Garnham 1966]. The level of infectivity in birds depends on the species of the bird, 
age and the environmental conditions (season).      
      Malaria parasites infecting reptiles belong to two subgenera Sauramoeba and 
Carinia. Of the reptilian malaria parasites known about nine species of Plasmodium 
are found exclusively in America, nine species in Africa, two species in the East 
Indies and Pacific Islands and two species restricted to Australia. Malaria parasites 
have been identified in the blood of lizards and snakes [Garnham 1966]. 
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Table 1. Other Plasmodium species and their definitive hosts [Garnham 1966] 
 
Host Plasmodium species 
Bird Host:  
house sparrow P. biguet 
blackbird P. giovannolai 
wild turkey P. griffithsi 
pigeon and doves P. matutinum 
  
Reptile host:  
fence lizard P. chiricahuae 
chameleon P. gologoense 
snakes P. tomodoni 
snakes P. wenyoni 
Rodent Host:  
grass rat 
 
P. aegyptensis 
mice P. berghei 
mice P. chabaudi 
mice P. yoelii 
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1.2 Life Cycle 
 
The life cycle of Plasmodium spp. [Fig 2] requires two hosts: an invertebrate  
 
(mosquito) and a vertebrate (mammal, reptiles and also birds). Malaria parasites are  
 
transmitted by the female Anopheles mosquito. There are about 380 species of  
 
Anopheline mosquitoes but only 60 are able to transmit the parasite [Schmidt et al. 
2000]. 
 
 
Fig 2. Malaria life cycle in mosquito and a human host     
[http://whyfiles.org/shorties/201malaria/images/life_cycle.gif] 
 
 
1.2.1 Mosquito stage development 
 
Sexual reproduction takes place within a definitive host, the mosquito. When a  
 
mosquito takes a blood meal both microgametocytes (male) and macrogametocytes  
 
(female) are ingested along with saliva. The macrogametocyte matures into a  
 
macrogamete while the microgametocyte undergoes exflagellation. An increase in pH  
 
due to the presence of dissolved carbon dioxide in blood stimulates this  
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transformation [Schmidt et al. 2000]. The microgametocyte matures into a  
 
microgamete, which further penetrates a macrogamete fertilizing it to form zygotes.   
 
These zygotes become elongate and motile and are known as ookinetes. The  
 
ookinetes penetrate the mosquito’s stomach wall and migrate to the hemocoel side of  
 
the gut where they develop into oocysts. Mature oocysts rupture to release  
 
sporozoites that migrate throughout the mosquito’s body. Sporozoites migrate to the  
 
mosquito’s salivary glands and become infective. Depending on the Plasmodium spp.  
 
sporozoite development takes place from 10 days to two weeks [Schmidt et al. 2000]. 
 
1.2.2 Exo-erythrocytic stage development 
 
The parasite enters a host when an infected mosquito takes a blood meal. During this  
 
process sporozoites are injected in the blood stream of the host. Inside the blood,  
 
circulating sporozoites disappear within a few minutes invade hepatocytes [Shin et.  
 
al. 1982]. Sporozoites are targeted to the liver through specific ligand-receptor  
 
interactions. Within the hepatocytes the parasites undergoes asexual reproduction to  
 
produce mature schizonts.  Sporozoites transform into trophozoites that feed on the  
 
host cell cytoplasm. Depending on the species the time varies for trophozoites to  
 
mature and begin schizogony. The parasite transforms into a schizont following the  
 
formation of many daughter nuclei (merozoites). Merozoites are released from the  
 
liver into the blood to initiate the erythrocytic cycle. Time taken for completion of the  
 
exo-erythrocytic stage depends on the Plasmodium spp.: 5 ½ to 6 days for P.  
 
falciparum, 8 days for P. vivax, 9 days for P. ovale and 13 days for P. malariae  
 
[Schmidt et al. 2000]. In some species such as Plasmodium ovale and P. vivax,  
 
sporozoites may become dormant cells and remain dormant in the liver stage  
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becoming reactivated (relapse) causing malaria several months or years after the  
 
mosquito bite. These dormant cells are called hypnozoites [Schmidt et al. 2000]. 
 
1.2.3 Erythrocytic stage development 
 
Merozoites released from the liver penetrate the red blood cells where they undergo  
 
further asexual development. Inside the erythrocytes, merozoites transform into  
 
trophozoites that feed on the cytoplasm of the host cell to produce a large food  
 
vacuole [Fig 3]. At this stage the parasite appears as a ring within the erythrocyte with  
 
a visible nucleus to one end. As the parasite grows and feeds on the host cytoplasm  
 
the food vacuoles disappear and pigment granules called hemozoin become visible in  
 
the vacuoles. The parasite further develops into early schizont then mature schizonts.  
 
Mature schizonts contain numerous erythrocytic merozoites that are released into the  
 
blood when the schizont ruptures. Released merozoites continue the cycle and invade  
 
uninfected red blood cells. Rupture of the host cell releases parasite metabolic wastes  
 
and hemozoin into the blood, a stage that is associated with symptoms of the disease.  
 
Red cells infected with the malaria parasite undergo hemolysis.   Active Kupffer cells  
 
of the liver ingest infected red blood cells killing the malaria parasites [Murthi et al.  
 
2006]. Some merozoites invade red blood cell also develop into schizonts others  
 
invade and develop into gametocytes. These gametocytes are then ingested by a  
 
susceptible mosquito when it takes a blood meal. 
 
1.2.4 Red blood cell invasion 
 
Organelles of the apical complex (microneme, rhoptries and dense granule) are  
 
involved in host cell invasion, formation and maintenance of the parasitophorous  
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vacuole. Host cell invasion involves initial recognition and attachment to the host cell  
 
by surface components of the merozoites [Sam-Yellowe 1996]. The merozoite first  
 
interacts with the surface of the red blood cells and re-orients the apical end of the  
 
complex towards the membrane. The contents of the apical organelles are released  
 
and a moving junction is formed between the merozoite and the red blood cell  
 
membrane. The parasite enters the vacuole by invagination of the red blood cell  
 
membrane around the parasite forming the parasitophorous vacuole (PV). The  
 
invasion and invagination of the red blood cells is facilitated by discharge of contents  
 
from the rhoptry and microneme. Following parasite entry into the host cell the red  
 
blood cell membrane is resealed [Aikawa et al. 1978]. 
 
 
Fig 3. Erythrocyte invasion                                    
[http://www.nimr.mrc.ac.uk/parasitol/blackman/images/invsion_full.gif] 
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1.3 Types and Prevalence of Malaria 
 
Plasmodium sp. infects humans, birds, rodents, primates and reptiles. The different  
 
Plasmodium sp. cause different types of malaria. Plasmodium falciparum causes  
 
malignant tertian malaria. Malignant tertian is a very severe form of fever. A very  
 
high fever (hyperpyrexia) develops and the body temperature may continue to  
 
increase until eventually death may occur.  
 
     Plasmodium falciparum accounts for approximately 50% of all deaths from  
 
malaria in tropical zones of the world [Schmidt et al. 2000]. Signs associated with  
 
malignant tertian malaria are: darkening of the gray matter of the brain and abundant  
 
pigment in other tissues of the body as seen in patients who succumb to the disease  
 
[Schmidt et al.2000]. Plasmodium falciparum requires high temperatures for optimal  
 
development and is almost exclusively predominant in areas of sub-Saharan Africa  
 
and South East Asia. Plasmodium vivax causes benign tertian malaria and accounts  
 
for more than 50% of all malaria cases in the world [Mendis et al. 2001]. Tertian  
 
malaria recurs every 48 hours in infected patients [Schmidt et al. 2000]. Symptoms of  
 
tertian malaria are myalgia, headache, diarrhea, nausea, vomiting and a cough [Oh et  
 
al. 2001]. Plasmodium vivax is prevalent in temperate regions of the world. 
 
     Plasmodium vivax merozoites are unable to penetrate mature red blood cells and  
 
invade only young erythrocytes known as reticulocytes. Plasmodium vivax  
 
merozoites penetrate only erythrocytes containing the Duffy antigen which serves as  
 
the receptor P. vivax mrerozoites [Schmidt et al. 2000].  Quartan malaria caused by  
 
Plasmodium malariae and P. ovale and tertian malaria caused by P. ovale are the two  
 
less common types of malaria. Quartan malaria causes a fever with paroxysms that  
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recur every 72 hours or every fourth day due to the schizogony and release of  
 
merozoites from infected cells, with invasion of new erythrocytes by Plasmodium  
 
malariae [Schmidt et al 2000]. 
 
1.4 Symptoms and Pathogenesis 
 
Early symptoms of malaria resemble the onset of a flu followed by periods of chills.  
 
These symptoms are mainly due to the host inflammatory response to the parasite.  
 
Destruction of the red blood cells gives rise to anemia and jaundice. Rupture of the  
 
infected red blood cells to release merozoites is correlated with the increase in body  
 
temperature giving rise to a fever. Body temperature rises rapidly fluctuating between  
 
this high temperature and normal body temperature within two to three hours. The  
 
time period for the stages of benign tertian is between 8 to 12 hours. The time period  
 
for stages in quartan malaria is a recurrence every 72 hours. As the disease progresses  
 
patients may feel symptoms such as headaches, body aches, sweating, malaise,  
 
nausea and vomiting. Specific symptoms are also associated with the different  
 
species. Complications associated with malaria vary according to the infecting  
 
species.  
 
     A Plasmodium falciparum infection can lead to severe anemia due to the  
 
destruction of both parasitized and nonparasitized erythrocytes, circulation of iron  
 
bound hemozoin and bone marrow suppression. Cerebral malaria is a one of the  
 
common complications of a Plasmodium falciparum infection. The progression of  
 
cerebral malaria involves the sequestration of Plasmodium falciparum infected red  
 
blood cells to the blood brain barrier endothelium [Tripathi et al 2007].  Adherence of  
 
RBCs involves the knob proteins and direct interaction with the endothelial cell  
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surface [Robert et al. 1996]. Cerebral malaria accounts for 10% of Plasmodium  
 
falciparum cases and if left untreated results in death. Cerebral malaria is a disease of  
 
the brain and is commonly accompanied by an extremely high temperature above  
 
108°F and psychotic symptoms. The disease is accompanied by generalized  
 
convulsions and a persistent coma. Mortality due to cerebral malaria is between 15-  
 
20% [Adhikari 2002].        
      
     Fluid accumulation in the lungs (pulmonary edema) is also associated with  
 
Plasmodium falciparum infection. Symptoms include difficulty breathing, coughing  
 
up blood, excessive sweating, anxiety and pale skin. This is often due to an over  
 
administration of intravenous fluids that can lead to a coma or death within a few  
 
hours [Schmidt et al. 2000]. Algid malaria occurs in 0.37% of malaria cases [Popov  
 
2005] and is characterized by a rapid development of shock. Blackwater fever is  
 
another condition associated with a Plasmodium falciparum infection. This is  
 
characterized by kidney failure, hemolysis and hemoglobinuria [Schmidt et al. 2000].  
 
Kidney failure can result in a coma or eventually death. Lysis of erythrocytes releases  
 
hemoglobin and its breakdown products into the blood. Free hemoglobin destroys the  
 
glomerulus in the kidneys and leaks into the urine [Schmidt et al. 2000]. The result is  
 
a dark discoloration in urine due to the presence of hemoglobin. 
 
 
 
1.5 Diagnosis 
 
The diagnosis of malaria is confirmed by identifying the parasite in the blood of a  
 
patient.  Accurate detection and treatment of malaria requires methods of rapid  
 
diagnosis. Direct visualization of a well-prepared thick or thin stained blood smear  
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using a microscope is one method of diagnosing the disease. Two types of blood  
 
smears can be prepared, thick or thin smears. Thick smears are used to identify the  
 
parasite in the blood when parasitemia is low. The thin smear is used to identify the  
 
specific Plasmodium species. Plasmodium falciparum can be detected by two fast and  
 
simple immunochromatographic tests.  
 
     Where microscopes are not available malaria antigens can be detected using 
various kits to do a rapid diagnostic test (RDTs).  These tests are quick and results are 
obtainable in minutes.  These tests are based on the dipstick principle [Iqbal et al. 
2004]. These tests use specific antibodies bound to a membrane to detect circulating 
parasite antigens (Gaye et al. 1998). The immunochromatographic test (ICT Malaria 
P.f/P. v) detects a Plasmodium falciparum histidine-rich protein (HRP-2) antigen. 
OptiMAL detects a parasite- specific lactate dehydrogenase (pLDH) [Gaye et al. 
1998. Presence of the parasite in human host can also be detected by molecular 
diagnosis by means of polymerase chain reaction (PCR) using genus and species 
specific primers. Serological diagnosis can also be used to detect malaria antibodies 
in individuals who have previously had Plasmodium infections.  Plasmodium sp. 
schizonts are used as the antigens to detect for malaria-specific antibodies in a 
patients serum [CDC] by indirect immunofluoresence assay (IFA).          
     None of these newer methods has had as much success as the standard peripheral  
 
blood smear study. Various stains are used in identifying the parasite and the species.  
 
Common stains used are Romanowsky [Lillie 1978], Giemsa [Shute et al.1963]  
 
Lieshman’s [Chatterjee 1980].  Smears are often prepared by finger prick, ear lobe stab  
 
or venipuncture. Malaria pigments can also be identified in circulating phagocytic  
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leucocytes in cases of partially treated infections and in bone marrow aspirates  
 
[Sheikh et al. 2003].  
 
 
1.6 Treatment 
 
The type of treatment and drug used depends on the parasite species causing the  
 
infection, clinical status of the host (age, sex, body type, immune status, symptoms,  
 
and associated health conditions), geographical area of the malaria diagnosis [CDC].   
 
Chloroquine is used to treat .P. falciparum sensitive strains of malaria and primaquine  
 
is used effectively against all strains of all species. Current suppressive treatment  
 
involves the use of choloroquine to suppress the erythrocytic stage of the parasite  
 
during development. Chloroquine is effective in destroying P. vivax gametocytes. In  
 
areas endemic with malaria all cases of fever are treated as malaria cases with doses  
 
of chloroquine being administered to a patient. Choloroquine is however ineffective  
 
in destroying P.  falciparum gametocytes and as a result does not prevent its spread. 
 
     In areas endemic with P. falciparum a single dose of both primaquine and  
 
chloroquine is usually administered. The constant recurrence of the disease is one of  
 
the main problems of controlling the disease. Recurrence is often due to incomplete  
 
treatments, re-infection, absence of effective immune responses and relapse of the  
 
disease as in the case of P. ovale and P. malariae where dormant hypnozoites can be  
 
re-activated. Plasmodium vivax can remain in the blood for months to years and cause  
 
recurrence of the disease. Plasmodium vivax or P. falciparum infection can recur  
 
within 8-10 days after the initial infection. P. vivax and P. ovale are known for  
 
causing recurrence of malaria [Omonuwa et al.2002].  
      
     Malaria recurrence of more than 12 months is less likely to be Plasmodium  
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falciparum [Omonuwa et al. 2002]. Plasmodium falciparum recurrence is caused by  
 
reinfection and recrudescence. Cases of recrudescence can be due to incomplete or  
 
inadequate treatment, antigenic variation or multiple infections by different strains  
 
[Omonuwa et al.2002]. Another major factor affecting treatment is the increase in the  
 
resistance of parasites to the antimalarial drugs. Drug resistance has been increasing  
 
over the years and also continues to spread across endemic regions [Tilley et al.  
 
2006]. 
 
 
1.7 Drug resistance 
 
Plasmodium falciparum has developed resistance to nearly all the antimalarial drugs  
 
currently available. Plasmodium vivax infection is normally treated with a dose of 25  
 
mg salt/kg of chloroquine over 36-48 hours + primaquine for 14 days. Plasmodium  
 
falciparum infection is treated by administering chloroquine or pyrimethamine with  
 
sulphadoxine /quinine/mefloquine/artemisinin and/or combinations as suppressive  
 
therapy.  Primaquine is administered as a gametocytocidal in a single dose. Specific  
 
treatment depends on the sensitivity of the patient and the severity of the infection.  
 
     A mixed Plasmodium vivax, P. falciparum infection is treated by administering  
 
chloroquine or related drugs. Administering chloroquine+Primaquine in a single dose  
 
treats chloroquine sensitive strains of Plasmodium falciparum. Within 48 hours after  
 
drug administration the number of parasites should be reduced by 75%. Treatment for  
 
chloroquine resistant strains requires different combinations of various drugs. The  
 
following drugs are usually administered, in tablet form: Quinine + Pyrimethamine/  
 
Sulfa, Quinine + Tetracycline /doxycycline, Artesunate + Mefloquine; Mefloquine +  
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Pyrimethamine/Suipha. Drugs used to treat malaria target different stages of the  
parasite life cycle.  Combinations of some of the named drugs can also be  
 
administered in the form of injections. Table 2 shows the classes of antimalarial drugs  
 
and the mode of action of the different types of drugs [Olliaro 2001].  
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 Table 2. Modes of action and resistance of the main classes of antimalarial drugs [Olliaro  
2001]. 
Pathway Drug Class Target Mechanisms of 
Action 
Mechanisms of 
Resistance 
Nucleic acid 
Metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heam 
detoxification 
 
 
 
 
 
 
 
Oxidative Stress? 
Type-1 
antifolates; 
Sulfonamides, 
Sulfones 
 
 
 
 
Type-2 
antifolates: 
Pyrimethamine, 
biguanides 
(proguanil, 
cycloguanil), 
trimethoprim 
 
 
 
 
 
 
Naphthoqinones 
(atovaquone) 
 
 
 
 
 
 
Type-1 
(4-amino-
quinolines) 
 
 
 
Type-2 
quinolines (aryl-
amino alcohols)  
Artemisinin-type 
compounds 
 
Formation of 
dihydropteroste 
from PABA+ 
pteridine 
catalysed by 
DHPS 
 
 
Reduction of di- 
to tetra-
hydrofolate 
(cofactor for the 
biosynthesis of 
thymidylate, 
purine 
nucleotides, 
aminoacids) by 
DHFR using 
NAPDH as 
cofactor. 
 
Mitochondrial 
functions 
(electron 
transport chain), 
blockade of 
pyrimidine 
synthesis 
 
Heam 
crystallization 
 
 
 
 
Same as Type-1 
 
 
Alkylation of 
unidentified 
target? 
Hydroxylation 
Mimic PABA; 
Compete for active 
site of DHPS 
 
 
 
 
 
Mimic 
dihydrofolate: 
compete for active 
site of DHFR 
 
 
 
 
 
 
 
 
 
Inhibits DHODase; 
mimics ubiquinone: 
competes for 
comples III 
 
 
 
 
Inhibition / 
termination of β-
haematin formation 
 
 
 
Same as Type-1  
 
 
Free radical 
formation through 
activation of the 
peroxide by binding 
with Fe(II)PPIX 
Mutaions at the 
binding site 
 
 
 
 
 
 
Mutations at 
binding site 
 
 
 
 
 
 
 
 
 
 
 
Mutations at 
Coenzyme Q 
binding site 
 
 
 
 
 
Multi-gene; 
altered 
accumulation at 
FV (reduced 
influx or 
increased efflux) 
Same as Type-1 
 
 
Unknown 
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1.8 Phylum Apicomplexa  
 
Plasmodium belongs to the phylum Apicomplexa. All members of this phylum are  
 
obligate intracellular parasites [Sam-Yellowe 1996]. Other members of the phylum  
 
include: Toxoplasma, which is transmitted by eating contaminated food, and can  
 
result in gastrointestinal diseases, Babesia another protozoan causes babesiosis and is  
 
transmitted to people by the bite from an infected tick. Within the phylum are  
 
numerous parasites known to be involved in macrophage, lymphocyte, endothelial  
 
cell and erythrocyte invasion [Sam-Yellowe l996]. Members of Apicomplexa possess  
 
specialized secretory organdies termed apical organelles [Sam-Yellowe 1996]. Apical  
 
organelles are found at the anterior end of the invasive stage of the parasite [Fig 4].  
 
Three of these organelles; the rhoptries, micronemes and dense granules play a role in  
 
host cell invasion and modification of the host cells during infection [Sam-Yellowe  
 
1996].  Within the apical complex are two to eight rhoptries, micronemes and several  
 
dense granules. 
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1.9 The Apical Complex organelle 
 
Fig 4. Diagram of the Apical Complex  
[http://www.impact-
malaria.com/FR/EPS/Formations_et_cours_internationaux/Formation_de_la_Liverpool_School_LSTMH/cours_li
verpool/malaria_template_fr/Section_1/images/merozoite.gif] 
 
 
The rhoptries are membrane-bounded organelles and are thought to be involved in  
 
erythrocyte attachment, invasion and formation of the parasitophorous vacuole  
 
membrane (PVM). The PV is described as a membrane-bound sack or vacuole, which  
 
is seen upon invasion of the erythrocytes. Erythrocytic stages of the parasite reside  
 
and develop within the parasitophorous vacuole [Aikawa et al. 1978]. The parasite’s  
 
surface is separated from the host cell cytoplasm by the PVM which acts as an  
 
interface at which host parasite interactions take place [Lingelbach et al 1997]. 
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1.10 Microneme proteins 
 
The micronemes like the rhoptries are membrane bound and consist of many types of  
 
proteins [Blackman et al. 2001]. Erythrocyte membrane glycoproteins of the Duffy  
 
binding protein family act as receptors for P. knowlesi and P. vivax merozoites  
 
[Miller et al. 1975, Miller et al. 1976]. Plasmodium knowlesi and P. vivax merozoites  
 
do not invade erythrocytes lacking the Duffy glycoprotein [Wertheimer et al. 1989,  
 
Haynes et al. 1988].  A175-kDa protein ligand has been identified in P. falciparum  
 
known as erythrocyte binding antigen EBA-175.  EBA-175 binds to erythrocytes  
 
[Orlandi et al. 1990] and may be involved in junction formation [Jakobsen et  
 
al.1998].   At least ten micronemal proteins have also been identified in Eimeria and  
 
Toxoplasma [Blacman et al. 2001] 
 
 
 
1.11 Dense granule proteins 
 
The dense granules are also membrane-bounded vesicles that release their granular  
 
contents by exocytosis into the parasitophorous vacuole (PV). A number of dense  
 
granules proteins have been isolated from different Plasmodium species. Four dense  
 
granule proteins have been identified in P. falciparum: ring infected surface antigen  
 
(RESA), ring membrane antigen (RIMA), two serine proteases, PfSUB- 1 and  
 
PfSUB-2 [Blackman et al. 2001]. A number of other proteins have been localized in  
 
the dense granules of Toxoplasma tachyzoites (GRA1-GRA8). The dense granule  
 
proteins localized all have a form of association with the PV [Blackman et al. 2001]. 
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1.12 Erythrocyte binding proteins and their identified binding domains 
 
Several erythrocyte binding proteins from the merozoite surface and the apical  
 
complex have been characterized. Erythrocyte-binding antigen (EBA- 175) [Sim et al.  
 
1998], shown to mediate invasion of red cells [Preiser et. Al 199], apical membrane  
 
antigen AMA-1 [Fraser et al. 2001], merozoite surface protein MSP-1 [Perkins and  
 
Rocco 1998], Duffy binding protein (DBP) [Xainli et al. 2003], RhopH [Sam- 
 
Yellowe et al.1991] and Py235 [Ogun and Holder 1996] binds to the erythrocyte  
 
surface membrane. In Plasmodium falciparum, merozoite invasion is initiated by  
 
binding of the merozoite surface protein MSP-1 to the red blood cells [Perkins and  
 
Rocco 1998].  
 
     To date approximately 10-11 such proteins have been identified, MSP-1 to MSP- 
 
11 [Sherman 1998]. MSP-1 binding is followed by interaction of the apical complex  
 
proteins including proteins from the micronemes and the rhoptries. Merozoite surface  
 
protein MSP-1 interacts with sialic acids on erythrocyte glycoprotein [Perkins and  
 
Rocco 1988]. Following this interaction other apical complex proteins are then able to  
 
bind to and interact with erythrocytes mainly rhoptry proteins. MSP-1 is part of a  
 
family of merozoite surface proteins and is found to be expressed in all species of  
 
Plasmodium [Barnwell et al. 1998].   
 
     A 21 amino acid sequence from EBA-175 of Plasmodium falciparum binds to  
 
glycophorin A on erythrocytes [Jakobsen et al. 1998]. This amino acid sequence  
 
(aa1076-96) binds via an initial sialic acid dependent step to erythrocytes. Delineation  
 
of this sequence gives a 12 amino acid sequence (aa1085-96) capable of binding to  
 
erythrocytes independent of sialic acid [Jakobsen at al. 1998]. The EBA-175 peptide  
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(aa1076-96) induces antibody formation in mice after conjugation with a purified  
 
protein derivative [Jakobsen et al. 1998]. AMA-1 is present in the apical complex  
 
organelle often times on the surface of Toxoplasma and Plasmodium zoites. AMA-1  
 
is thought to have erythrocyte binding function and has a role in invasion [Barnwell et  
 
al. 1998]. The MAEBL gene family proteins have also been localized by  
 
immunoelectron microscopy (IEM) in Plasmodium yoelii and localized to the surface  
 
of merozoites within schizonts. These MAEBL proteins have been identified as  
 
erythrocyte binding proteins.                   
 
     AMA-1 (apical membrane antigen 1) a micronemal protein was found to be highly  
 
conserved among Plasmodium spp. and is thought to have an adhesive or receptor- 
 
binding function  during red blood cell invasion [Barnwell et al. 2005].  In  
 
Plasmodium yoelii YM AMA-1 domains 1 and 2 facilitate erythrocyte binding to  
 
mouse and rat erythrocytes [Fraser et al. 2001].  Antibodies against Plasmodium  
 
falciparum AMA-1 are shown to inhibit cell invasion by the parasite [Barnwell et al.  
 
2005].  The gene encoding AMA-1 has been cloned in several Plasmodium species  
 
including P. falciparum, P. vivax, P. knowlesi, P. chaubaudi and P. fragile. AMA-1 is  
 
an 83-kDa protein in P.falciparum [Barnwell et al. 2005] and is conserved among  
 
apicomplexans. 
 
1.13 Rhoptry proteins 
 
Several rhoptry proteins have been characterized to date (Table 3).  The Rhop-H/Clag  
 
proteins or high molecular mass rhoptry protein complex contain three distinct  
 
proteins, the 155/140 RhopH-1, 140/130 RhopH-2 and the 110/105 kDa RhopH-3  
 
proteins [Barnwell et al. 2005].   RhopH-1 has been identified as a member of the  
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cytoadherence-linked asexual gene (clag) family [Barnwell et al. 2005]. Clag 9-  
 
specific antibodies immunoprecipitate the RhopH complex and Clag 9 was detected  
 
in the complex purified by antibodies to RhopH2 [Barnwell et al. 2005]. These data  
 
suggests that the RhopH complex could be a mix of clag components [Kaneko 2001].  
 
Five members of the RhopH-1/clag family have been evaluated in Plasmodium  
 
falciparum HB3 parasites, clag2, clag3.1, clag3.2, clag 8 and clag9 [Kaneko et al.  
 
2005].  
 
     The rhoptry-associated protein (RAP) consists of three lower-molecular-mass  
 
proteins, the 86 kDa RAP-1 and 42/39 kDa RAP-2, RAP-3 proteins [Baldi et al.  
 
2002].  The rhoptry-associated membrane antigen (RAMA) is a 60 kDa GPI-linked  
 
protein formed from a 170 kDa precursor, this protein is discharged from the  
 
rhoptries during invasion and is found in the PV during early ring stages of the  
 
parasite life cycle [Barnwell et al. 2005]. Other molecules associated with the  
 
rhoptries include a 52 kDa protein, and a novel Plasmodium falciparum rhoptry  
 
protein, PfRhop 148 [Lobo et al. 2003]. The 229 kDa repetitive organellar protein  
 
(ROPE) is also thought to be involved in the invasion process and may be involved in  
 
the mimicry of spectrin [Werner et al. 1998]. 
 
      Due to their high conservation among Plasmodium spp. these asexual stage  
 
proteins have been targeted as malaria vaccine candidates [Sam-Yellowe et al. 2000].   
 
A majority of the rhoptry proteins are secreted during merozoite invasion, many of  
 
which disappear during early development of the parasite suggesting that their role is  
 
in invasion. The Rhop-3 protein has been found to be conserved among Plasmodium  
 
falciparum, and the rodent species P. berghei, P. chabaudi and P. yoelli [Anthony et  
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al. 2000, Sam-Yellowe et al. 1998].    
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1.13.1 RhopH-3 
 
RhopH-3 is distinct gene product of the high molecular weight complex, RhopH.  
 
The Rhop-3 protein is secreted into the erythrocyte membrane during invasion and is  
 
an erythrocyte binding protein [Sam-Yellowe et al. 1988, Sam-Yellowe and Perkins  
 
1991]. The gene encoding the Rhop-3 protein consists of 7 exons (Fig 5.) [Brown and  
 
Coppel 1991].   
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The most conserved regions of the protein lies within the C-terminus (the second half 
of exon 6 amino acid #548 to #665) and the beginning of exon 3 (amino acid #59 to 
#2 10) [Wang et al. 2006].            
     There is a strong human immune response to the C-terminus of the Rhop-3 protein 
among sera from individuals in different malaria endemic regions [Yang et al. 1996]. 
This region of the protein is highly conserved among Plasmodium species.   
Immunization of mice using proteins encoded by the C-terminus of P. yoelii Rhop-3 
and the full P. berghei Rhop-3 protein have also been shown to induce protection 
against the rodent parasites, P. yoelii and P. berghei [Wang et al. 2006]. The Rhop-3 
protein is therefore considered a strong candidate for an asexual stage malaria 
vaccine. The Rhop3 protein is an erythrocyte binding protein involved in red blood 
cell invasion however, the binding domain of the Rhop-3 protein has not yet been 
characterized.  
     The 140/130/110 kDa Rhop-H/Clag complex binds directly to intact mouse 
erythrocytes, this complex also binds to membranes and inside-out vesicles of mouse, 
human, saimiri, rhesus rat and rabbit erythrocytes [Sam-Yellowe et al.1991]. This 
complex was also found to bind specifically to liposomes made using different types 
of phospholipids [Sam-Yellow et al. 1991].  Phosphatidylethanolamine (PE) 
containing phospholipids block binding of the rhoptry protein complex to mouse cells 
[Sam-Yellowe et al. 1991]. Results of these studies suggest that the complex may 
interact directly with sites in the lipid bilayer of the red blood cell membrane [Sam-
Yellowe et al. 1991]. The binding domains for a number of erythrocyte-binding 
proteins have already been characterized, however the binding domain of the Rhop-3 
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proteins is not yet known. The aim of this study is to identify the binding domain the 
Rhop-3. 
 
1.14 Hypothesis 
 The binding domain of the Rhop-3 protein lies within the C-terminus of the protein.     
 
1.15 Aim   
 To identify the erythrocyte binding domain of the Plasmodium merozoite rhoptry 
protein Rhoph-3. 
 
1.16 Significance of Project 
Knowledge of the domain will be important to determine if the binding epitope can 
induce protective immune responses. 
If the binding domain induces an immune response it may be a suitable protein target 
for vaccine studies. 
 
1.17 Objectives   
1.   Clone Rhop-3 exons using the vectors, pDisplay (Invitrogen), pRE4 and 
pEGFPNI and express clones in COS-7 cells. 
2. Use erythrocyte rosetting assays to determine Rhop-3 binding to erythrocytes and 
use Rhop-3 specific antibodies in inhibition studies to evaluate specificity of binding.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
2.1 Parasite maintenance                                                                                                                 
Plasmodium berghei obtained from Dr. Mark Wiser, Tulane University and 
Plasmodium yoelii obtained from Dr. Carole Long, National Institute of Health, 
infected Swiss Webster mice were maintained as described [Sam-Yellowe et al.1998]. 
Infected erythrocytes (1x106 cells/ml) were collected by cardiac bleeding of SW 
mice. Infected blood was collected in citrate phosphate dextrose buffer (CPD) and 
washed 3X in non-sterile RPMI 1640 and centrifuged for 5 minutes each. Infected 
erythrocytes were used for weekly passaging of parasites into female SW mice 
maintained at the animal facilities of Cleveland State University. Plasmodium 
falciparum strain FCR-3 were maintained and grown in human erythrocytes 
according to the method of [Trager and Jensen 1976]. 
2.2 Culture of mammalian cells                                                                                                                 
COS-7 green monkey kidney cells obtained from the American Type Culture 
Collection (ATCC) were cultured and used to express recombinant proteins. Cells 
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were grown in open screw capped 25cm2 flasks and maintained in complete 
Dulbecco’s Modified Eagle’s Medium (DMEM) plus 10% heat-inactivated fetal 
bovine serum (FBS) (Invitrogen, CA) in a 37°C incubator, gassed with 5% C02, 95% 
air. Cell monolayers were grown to confluence and routinely passaged 3-4 days by 
removing spent culture medium and replacing with fresh DMEM [Fraser et al. 2001]. 
2.3 Isolation of genomic DNA 
Schizont-infected erythrocytes of P. berghei, P. yoelii and P. falciparum were lysed 
with tris pH 8.8 followed by centrifugation at 15,000 rpm (JA-20 rotor Beckman) for 
10 minutes to obtain schizont pellets. The pellets were then homogenized in 600u1 
TES buffer (10mM Tris-HCL p117.6, 50 mM EDTA pH8.0, 0.1 % SDS) containing 
1mg/ml proteinase K.  Lysed erythrocytes were then incubated in a 37ºC water bath 
for 30 minutes. 500µl phenol chloroform (1:1) mix was used to extract schizont DNA 
and the DNA precipitated in 70% ethanol and resuspended in distilled water. Isolated 
DNA was separated by agarose gel electrophoresis using a 0.7% agarose gel, 
visualized using ethidium bromide. Isolated DNA was used as templates for PCR. 
DNA concentration was obtained using Beckman DU Series 500 Spectrophotometer. 
2.4 RNA Isolation 
RNA was isolated from schizont pellets using RNAzol B Isolation method (Tel-Test 
Inc). Pellets were homogenized with RNAzol B. RNA was extracted in chloroform 
and precipitated in isopropanol. The white-yellow RNA pellet was washed with 75% 
ethanol, air dried and dissolved in 25ul DEPC water. Isolates were analyzed by 
formaldehyde RNA gel electrophoresis on a 1% agarose gel. 
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 2.5 Protein extraction.    
Plasmodium berghei, P. yoelii and P. falciparum protein samples were extracted by 
adding 100-150µl 1% Triton X 100 to schizont pellets. The pellets were vortexed and 
placed on ice for 5 minutes and vortexed again. This vortexing, ice incubation cycle 
was repeated 5 times for a combined 30 minutes extraction. The suspension was then 
centrifuged for 5 minutes at 14,000 rpm and the supernatant removed and collected 
into a fresh tube and the supernatant and pellets frozen at -20°C. The protein 
concentration was then determined by using the method of Bradford.  Protein samples 
were used for SDS-PAGE analysis, transferred to nitrocellulose paper (NCP) and 
western blotting techniques performed using specific anti-Rhop-3 antibodies Ab”686” 
[Yang et al, 1996], Mab 1B9 [Sam-Yellowe et al., 1988], Ab “Fl”, Ab “T1” and 
pooled Ab “Fl”+ “Fl2” [Wang et al., 2006]. Normal rabbit antisera NR701 and 
normal mouse antisera were used as negative controls. 
2.6 PCR Amplification                                                                                                                        
PCR amplification was performed in a 50 µl reaction mixture using l0X Mg++ free 
PCR Buffer (500mM KCL, 100mM Tris HCL (pH 9.0), 15mM MgCl2, 200 μM of 
each dNTP, 10pM of each primer, 5 units of DNA polymerase using the following 
cycling parameters: one cycle of 2 min at 94°C, 40 cycles of 15s at 94°C, 30s at 
45°C, and 2 min at 68°C followed by 1 cycle of 5 min at 68°C and cooled to 4°C. 2µl 
of template DNA was used in the reaction mixture. A negative control tube 
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containing no DNA was also included. A 1% ethidium bromide stained agarose gel 
was used to analyze and visualize the PCR products. 
2.7 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)  
The total RNA from the rodent Plasmodium parasite was reverse transcribed into 
complementary DNA (cDNA) and the strands amplified using designed primer pairs 
based on the sequences of the Rhop-3 exons. The primer pairs for exons l-3, mini-
exons 4/5, exons 6-7 and full-length were designed for amplifying the exons by RT-
PCR. 
2.7.1 Plasmid Amplification  
A plasmid vector was used to transfect mammalian cells for expression of the 
recombinant proteins. The plasmid is a mammalian expression vector designed to 
target recombinant proteins to the surface of mammalian cells.  
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2.7.2. Feature of the Plasmid 
Figure 7.  Diagram of Plasmid pDisplayTM (Invitrogen) 
Plasmid pDisplay (Fig. 7) has an N-terminal cell surface targeting signal and a C- 
terminal transmembrane anchoring domain and has the advantage of having the 
protein of interest expressed on the cell surface. The plasmid facilitates directional 
cloning of the desired insert within its multiple cloning site. Recombinant proteins 
expressed have a hemagglutinin A and myc tag fused to the C-terminus of the protein 
allowing for detection of the protein by immunofluorescence or western blot.   
Proteins expressed are fused at the N-terminus to the murine Ig k-chain allowing the 
protein to enter the secretory pathway and fused at the C-terminus to the platelet 
derived growth factor receptor (PDGFR) transmembrane domain for anchoring the 
expressed protein to the cell surface (www.invitrogen.com). 
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2.8 Construction of Recombinant Plasmids 
 
 Plasmid pDisplay was used to construct recombinants containing the full length 
Rhop-3 gene and fragments of the Rhop-3 gene.    Primers containing the appropriate 
restriction sites were used to amplify Rhop-3 by PCR and RT-PCR and the products 
were gel purified. The purified products were cut at their appropriate restriction sites 
and the digested products separated by gel electrophoresis on a 1% agarose gel. DNA 
was visualized using ethidium bromide. Separated bands were further excised from 
the gel and gel purified using (S.N.A.P Gel Purification kit).  Purified products were 
ligated to the plasmid vector digested with the same restriction enzymes. Ligation 
was carried out overnight at 12°C (Thermolyne ThermoKool, CA, U.S.A). The 
recombinant plasmid was used to transform E. coli strain DH5α cells (Invitrogen). 
Transformants were selected after growth on antibiotic selective media and inoculated 
into LB broth.   Overnight cultures were used to isolate purified recombinant using an 
endotoxin-free purification kit (Qiagen).  The isolated recombinant plasmid was used 
to transfect COS-7 cells to optimize protein expression. 
2.9 Seeding of COS-7 cells 
Media was removed from a confluent flask of cells.  2mls of trypsin EDTA was 
added to dislodge adherent cells.  The cells were washed in 10-12ml incomplete 
media (DMEM without serum) and spun for 5 minutes at 1250rpm. The supernatant 
was discarded and the cells resuspended in 2ml incomplete media. 10μl of the cell 
suspension was used to determine the concentration using a hematocytometer.  A cell 
suspension of 160,000 cells/ml was made up in incomplete media. 250μl of the cell 
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suspension was added to each well of a Poly-D-Lysine coated 24-well plate or 8-well 
slide.  The cells were then let to settle for 3hrs at 37˚C in the incubator.   
2.10 Transfection with Lipofectamine 
A 3% Lipofectamine solution was made up in incomplete media and incubated at RT 
for 15 minutes.  DNA solutions were made in incomplete media (100ng/well), 
combined with an equal volume of Lipofectamine solution and incubated at rtp for 20 
minutes. Incomplete media was added to each DNA solution (200μl/well).  250μl of 
each DNA solution was added to each well and the plates incubated for 4hrs at 37˚C.  
Media on the transfected cells was replaced with complete media (DMEM with 10% 
serum) and the cells incubated for 42-44hrs.  
2.11 Erythrocyte binding assay using spent culture supernatant 
Mouse and human blood were used to carry out erythrocyte binding assays. Mouse 
blood was collected by cardiac bleeding of BALB/c mice into citrate-phosphate- 
dextrose (CPD) and washed 3X in RPMI-1640. Erythrocyte binding assay was 
performed as described previously (Perkins and Rocco 1988).  Spent culture 
supernatant (SCS) was collected from P. falciparum cultures and from short-term 
cultures of rodent Plasmodium schizont-infected erythrocytes. Unlabeled SCS (300-
600µl) was added to mouse erythrocytes (l00µl) resuspended gently and incubated for 
30 minutes at room temperature. The cell suspension was then layered over 0.5ml 
silicone fluid (Dow Coming 550 fluid) in a 1.5ml eppendorf tube and centrifuged for 
2 minutes at 14,000 rpm. The supernatant was then collected and the cell pellet 
resuspended in 0.5ml RPMI-1640. The cell suspension was layered over 0.5ml 
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silicone fluid and centrifuged for 2 minutes.   Supernatant was removed and discarded 
and the cells gently resuspended in 0.5M NaCI and incubated for 10 minutes at RT. 
The suspension was then centrifuged for 2 minutes at 14,000 rpm. The eluate was 
removed and mixed with protein electrophoresis sample buffer and analyzed on a 5 to 
15% SDS-gradient gel [Perkins and Rocco 1988]. 
2.12 Protein Expression and detection 
Recombinant plasmids containing the genes of interest isolated from bacterial cells 
were used to transfect COS-7 cells (African Green Monkey Kidney Fibroblasts) using 
Lipofectamine 2000TM (Invitrogen), Lipofectin, Lipofectamine 2000TM and Plus 
reagent (Invitrogen), Lipofectin and Plus reagent. The plasmid used allowed for the 
encoded proteins to be expressed on the surface of the mammalian cells. Expression 
of the protein of interest was analyzed by Immunofluorescence Assay (IFA) with 
Rhop-3 specific antibodies. 
2.13 Rosetting Assay 
Erythrocyte rosetting technique was used to study the binding of Rhop-3 to 
erythrocytes. The assay was carried out to evaluate the binding of uninfected 
erythrocytes to COS-7 cells expressing Rhop-3 on the surface membrane. The 
rosetting assays were performed using a standard procedure [Adams et al. 2000]. 
COS-7 cells were plated into Poly-D-Lysine coated 24-well culture plates and Poly-
D-Lysine coated 8-well culture slides.  COS-7 cells were transfected with 
recombinant pDisplay DNA using Lipofectamine 2000TM (Invitrogen), Lipofectin, 
Lipofectamine 2000TM and Plus reagent (Invitrogen), Lipofectin and Plus reagent in 
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Dulbecco modified Eagle medium (DMEM; Sigma) without serum.   After a 4hr 
incubation the transfection medium was replaced by DMEM with 10% fetal bovine 
serum and incubated for 24hr, 42hr, 44hr or 60hrs. The transfected cells were 
incubated for 2hr at room temperature with human or mouse erythrocytes (10% final 
suspension washed in DMEM without serum). The cells were then washed three 
times in PBS to remove non-adherent erythrocytes. Rosettes were counted in 30 fields 
at a magnification of X200 to evaluate the binding. Rosettes were counted as positive 
when adherent erythrocytes cover more than 50% of the cell surface. These 
experiments were carried out in three replicates and repeated three times [Adams et 
al. 2000]. 
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CHAPTER III 
 
RESULTS 
 
 
3.1 Western Analysis 
Western blot assays using anti-Rhop3 mouse antibodies T2, FL1+FL2 and F2 were 
used to identify Rhop-3 in Plasmodium falciparum (lane 3), P. berghei (lane 2) 
extracts separated by SDS-PAGE gel electrophoresis [Fig 8].  The mouse antibodies 
T2, FLI+FL2, F2 recognized the rodent Plasmodium Rhop-3 [Fig. 8 (a), (b), (d) lane 
2] with no Rhop-3 identified in Plasmodium falciparum [Fig 8. (a), (b), (d) lane 3].  
No proteins were detected using the normal mouse antibody [Fig 8. (e)].  Rabbit 
antibody #686 identified Rhop-3 in the human malaria species and also in the rodent 
species [Fig 8. (c) lane 3 and 2 respectively] . 
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Figure 8.  Western Blots using Rhop-3 specific antibodies.    The antibodies react with the 110- 
 
kDa protein from P. berghei and P. falciparum.  
 
 
3.2 Recombinant Constructs 
 
PY1412 sequence was amplified from Plasmodium yoelii and P. berghei genomic 
DNA by PCR to obtain a partial fragment of the Rhop-3 gene to be inserted into the 
vector pDisplay. The amplified fragment was ~960bp [Fig 9. lanes 2-5] and was 
conserved in Plasmodium yoelii and P. berghei 
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Figure 9. PY1412 PCR products amplified from genomic P. yoelii and P. berghei.                                    
 
P. berghei PY1412pDisplay (lane 2), P. berghei PY1412/pEGFPN1 (lane 3), P. yoelii  
 
PY1412/pDisplay (lane 4), P. yoelii PY1412/pEGFPN1 (lane 5), water control (lane 6) 
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       1.0 
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Figure10. PY1412 PCR products amplified from recombinant pDisplay/PY1412.                                                                
 
PY1412/pDIS (lane 2-4),water control (lane 5) Purified Plasmodium yoelii PY1412 was digested  
 
using the restriction enzymes BglII and SalI and ligated to BglII +SalI disgested pDisplay. The  
 
ligation mixture was used to transform Escherichia coli DH5α cells and the recombinant DNA  
 
isolated.  The Plasmodium yoelii PY1412 sequence was amplified from the recombinant DNA and  
 
~960bp fragment recovered [Fig 10. lanes 2-4].                        
 
  40
        KB         1           2         3         4        5
 
 
 
 
 
     10.0 
        
      3.0 
 
 
     
     1.0 
 
      
     0.5 
Figure 11. PY1412 PCR products amplified from recombinant pEGFPN1                      
 
PY1412/pEGFPN1(lanes 2-3), control exon 7 primers (lane 4),  (5) water control                                    
 
water control (lane 5). Purified Plasmodium yoelii PY1412 was digested using the restriction  
 
enzymes BamHI and HindIII and ligated to BamHI +HindIII digested pEGFPN1. The ligation  
 
mixture was used to transform Escherichia coli DH5α cells and the recombinant DNA isolated.   
 
The Plasmodium yoelii PY1412 sequence was amplified from the recombinant DNA and   
 
recovered a fragment around 960bp, however there were also two other bands recovered at ~  
 
1.5kb and 2.0kb  [Fig 11 lanes 2-3].                                                                                            
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Figure 12. Exon 1 to 3 RTPCR products amplified from P. falciparum RNA (lanes 2-5) exon 1-3 
(lane 7) water control  (lane 8) enzyme control. Using designed primers exon 1 to exon 3 of 
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Plasmodium falciparum was amplified from isolated P. falciparum RNA by RT-PCR for insert 
into the vector pDisplay. The amplified fragment was ~1.1kb [Fig 12 lanes 2-5] 
 
           
     10.0 
       10.0         
         3.0 
         1.0 
 
         0.5 
KB   1   2   3 
Figure 13. Exon 1 to 3 RTPCR products amplified from P. falciparum Dd2 (lane 2-3) exon 1-3  
 
(lane 5) water control  (lane 6) enzyme control Using designed primers exon 1 to exon 3 of  
 
Plasmodium falciparum was amplified from isolated P. falciparum RNA by RT-PCR for insert  
 
into the vector pDisplay. The amplified fragment was ~1.1kb [Fig 12 lanes 2-3]. 
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Figure 14. Exon 1 to 7 and 6-7 RTPCR products amplified from P. falciparum Dd2 exon 1-7  
 
(lanes 2-8), exon 6-7 (lane10-15), water control (lane 16). Using designed primers exon 1 to exon 7  
 
and exon 6 to exon 7 of Plasmodium falciparum were amplified from isolated P. falciparum RNA  
 
by RT-PCR for insert into the vector pDisplay. The amplified fragment exon 1-7 was ~2.7kb [Fig  
 
14 lanes 2-8], the sequence from exon 6 -7 was not amplified [Fig 14 lanes 10-15]. 
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Figure 15. Exon 6 and  7 PCR products amplified from P. falciparum FCR-3 DNA exon 7 (lane  
 
2), exon 6 (lane 3), water control (lane 4). Using designed primers exon 6 and exon 3 of  
 
Plasmodium falciparum was amplified from isolated P. falciparum genomic DNA by PCR for  
 
insert into the vector pDisplay. 
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 Figure 16.  Full-length recombinant P. falciparum Rhop-3 DNA (2-5) exon 1-7 recombinant  
 
pDisplay/1-7. Plasmodium falciparum recombinant DNA encoding exon 1-7 was isolated and  
 
purified from transformed Escherichia coli DH5 α [Fig 16 lanes 2-4].    
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 Figure 17.  Recombinant P. falciparum Rhop-3 DNA exon 1-3  (2-6) exon 1-3 recombinant  
 
pDisplay/1-3 Plasmodium falciparum recombinant DNA encoding exon 1-3 was isolated and  
 
purified from transformed Escherichia coli DH5 α [Fig 17].    
 
                                                                         
Figure 18.  Recombinant P. falciparum Rhop-3 PCR products (2-3) exon 1-7 (4-5) exon 1-3 (6,7,) 
controls (8) water control primers for exon 1 and exon7 and exon 1 and exon 3 were used to 
amplify these fragments from the recombinant DNA.  From the gel the water control appears to 
be contaminated and the products do not correspond with the fragments amplified from RNA.                                         
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Figure 19.  Recombinant P. falciparum Rhop-3 exon 1-3 and exon 7 (2) recombinant exon 1-3 (4) 
recombinant exon 7. Plasmodium falciparum recombinant DNA encoding exon 7 was isolated and 
purified from transformed Escherichia coli DH5 α [Fig 19].           
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3.3 Erythrocyte binding Assay 
 
COS-7 cells were transfected with 100ng of recombinant DNA using a   
 
LipofectamineTM reagent and incubated for 44hr to allow for protein expression.   
 
After 44hrs COS-7 cells expressing the protein of interest were used to carry out  
 
erythrocyte binding assays.  50µl of a 10% RBC suspension was added to each well  
 
as demonstrated below [Table 4].  Sal1 the Duffy binding protein was used as a  
 
positive control. The recombinant SalI expresses region II of the Plasmodium vivax  
 
Duffy binding protein (PvDBPII) which binds to Duffy positive human RBC.  
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Table 4.  Seeding and Transfection layout of 24 well plates.  
Sal1 Sal 1 Sal 1 pDisplay/
1412
PDisplay/
1412
PDisplay/
1412
pEGFPN1 pEGFPN1 pEGFPN1      -VE       -VE   -VE
Sal1 Sal 1 Sal 1 pDisplay/
1412
PDisplay/
1412
PDisplay/
1412
pEGFPN1 pEGFPN1 pEGFPN1      -VE       -VE   -VE
Mouse 
RBC 
Human 
 RBC 
 
COS-7 cells were transfected with 100ng of recombinant PDIS-PY1412 DNA using a 
LipofectamineTM reagent and incubated for 44hr to allow for protein expression.  
After 44hrs COS-7 cells expressing the protein of interest were used to carry out 
erythrocyte binding assays.  50µl of a 10% mouse RBC suspension was added to each 
well transfected with PDIS-PY1412 and 50µl of a 10% human RBC suspension 
added to the SALI positive control as demonstrated below [Table 5].  There was a 
high percentage of binding of uninfected mouse RBC to the PY1412 recombinant 
protein with 20-30 RBC attached to each COS-7 showing resetting [Table 5].  There 
was some binding seen in the positive control also.  Human RBC did not bind to the 
PY1412 protein and mouse RBC did not bind to the Plasmodium vivax DBP. 
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Table 5.  Results from Binding Assay showing binding of Recombinant 
Plasmodium yoelii pDisplay/PY1412 to COS-7 cells 
                                        
0 0 0 49 45 63
0 0 0 0 0 0
14 9 7 0 0 0
0 0 0 0 0 0
Human 
RBC 
Mouse 
RBC 
Recombinant 
PY1412/pDisplay
                 Pv-DBPIISal1 
 
Using the PvDBPIISalI as control, the number of rosettes formed with the 
Plasmodium vivax protein was considered total binding and taken to be 100% 
binding.  The number of rosettes of the Plasmodium yoelii protein were then 
compared to the total number of rosettes from P. vivax [Table 6]. 
Table 6. Percent Binding of Plasmodium yoelii recombinant Rhop-3 protein to  
 
COS-7 cells compared to binding in the Sal as control. 
                        
  Sample 
Pv-DBPIISal1 P. yoelii Recombinant   
pDisplay PY1412 
Average 
 (3 wells) 
10 52.3 
% Binding 100 523 
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Rosettes were counted as positive when more the half the surface of the COS-7 cell 
had attached RBC’s as seen in the photographed fields below [Figure 21] taken of the 
PvDBPIISalI positive control. The total number of rosettes seen in 30 fields were 
counted.                                                                                                                                                    
             
      free RBC                                                                        COS-7 cell with more than 50% of the                                                                
                                              surface covered with RBCs 
 
Figure20. Rosetting of Human RBC to                   Figure 21. Rosetting of Human to COS-7 cell  
 
expressing Pv-DBPIISal1                                           RBC COS-7 cell expressing Pv DBPIISal1                                               
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Figure 22. Control well showing unbound RBCs  
Using the vector pDisplay three recombinant Plasmodium falciparum Rhop-3 
proteins including the full-length Rhop-3 protein were expressed using the COS 
system, the presence of the protein was detected by IFA’s using 4 different anti-
Rhop-3 specific antibodies. The pDisplay vector was also used to express a protein 
encoded within the C-terminus of the Plasmodium yoelli Rhop-3 gene which was also 
detected by IFA using anti-Rhop-3 antibodies [Table 7].   
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Table 7. Recombinants used in Transfection and Binding Assays  
R e c o m b i n a n t s
A t t e m p t e d
C l o n e s
M a d e
T r a n s f e c t io n
&  B i n d in g
R o s e t t e s R e s u l t s I F A R e s u l t s
P .  f a l c i p a r u m
V e c t o r -  p D i s p l a y
     E x o n  1
      E x o n  2
     E x o n  3
     E x o n  6
     E x o n  7
     E x o n  1 - 3
     E x o n  6 - 7
     E x o n  1 - 7
V e c t o r  p E G F P N 1 *
     E x o n  1
      E x o n  2
     E x o n  3
     E x o n  6
     E x o n  7
V e c t o r -  p E G F P N 1 a
     E x o n  1
      E x o n  2
     E x o n  3
     E x o n  6
     E x o n  7
Y E S
Y E S
Y E S
Y E S
Y E S
Y E S
N O
N O
N O
N o
b i n d i n g
N o
b i n d i n g
Y E S
Y E S
Y E S
F l u o r e s c e n c e
F l u o r e s c e n c e
F l u o r e s c e n c e
P .  y o e l i i
V e c t o r  – p D i s p l a y
   P Y 1 4 1 2
V e c t o r  p E G F P N 1
   P Y 1 4 1 2
V e c t o r -  p E G F P N 1 a
    P Y 1 4 1 2 a
Y E S
Y E S
Y E S
Y E S
Y E S * S o m e
b i n d i n g
Y E S F l u o r e s c e n c e
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Expression and binding of the Plasmodium vivax DBPII to human RBC was observed 
in eight independent experiments and expression and binding of the Plasmodium 
yoelii PY1412 mouse RBC observed in one independent experiment [Table 8].                       
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Table 8: Results obtained from attempted Binding assays 
 
Date Assay DNA
7/7/2007 Transfection & Binding Assay 1ug
* regular plates
7/30/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates
7/31/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates
8/11/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates
8/7/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates & slides IFA
8/8/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine slides (IFA)
8/14/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine 
10/8/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine 
10/10/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine 
10/11/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates
10/31/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine slides for (IFA)
11/1/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates
Balb /cJ & Balb / cBy J  mice  ~6 wk old
11/28/2007 Transfection & Binding Assay 1ug
*poly-D-Lysine plates 5ug
Balb /cJ & Balb / cBy J  mice
newly made and  transformed PY1412 recombinant
Results
Human Blood                                          Rosettes                             Mouse Blood                               Rosettes
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                   0
Negative Control  -                                        0                                       Negative control                                    0
(untransfected cells with blood added)            
positive control Sal 1                                    0                                        positve control Sal 1                             0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant               49.45,43
14, 9, 7  
 36,30,60     
 36,30,60     
 0             
14,20,16    
 0        
 5,8,5   
pEGFPN1                                                    0                                      pEGFPN1                                              0
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                                              positve control Sal 1                              0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
pEGFPN1                                                    0                                      pEGFPN1                                              0
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                                            positve control Sal 1                             0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
pEGFPN1                                                    0                                      pEGFPN1                                              0
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                                            positve control Sal 1                             0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0                              positve control Sal 1                                        0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0                              positve control Sal 1                                        0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0                              positve control Sal 1                                        0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Full length ( 1-7)                                           0                                     Full legthFull-length (1-7)                          0
Exon 1-3                                                     0                                       Exon 1-3                                               0
Exon 7                                                        0                                      Exon 7                                                   0
Negative Control  -                                                                 Negative control                                     0
positive control Sal 1                                                              positve control Sal 1                           0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Full length ( 1-7)                                           0                                     Full legthFull-length (1-7)                          0
Exon 1-3                                                     0                                       Exon 1-3                                               0
Exon 7                                                        0                                      Exon 7                                                   0
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0,0,0                                positve control Sal 1                                0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Full length ( 1-7)                                           0                                     Full legthFull-length (1-7)                          0
Exon 1-3                                                     0                                       Exon 1-3                                               0
Exon 7                                                        0                                      Exon 7                                                   0
Negative Control  -                                                                      Negative control                                     0
positive control Sal 1                                                              positve control Sal 1                                0
                                              pDisplay 1412 recombinant                
                                                   Negative Control  
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0                                     positve control Sal 1                                0
pDisplay1412 recombinat -                         0                                     pDisplay 1412 recombinant                    0 
Negative Control  -                                        0                                       Negative control                                     0
positive control Sal 1                                    0                                     positve control Sal 1                                0
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Poly-D-lysine coated 8-well slides were seeded with COS-7 cells. COS-7 cells were 
transfected with recombinant PDIS-PY1412 and incubated 44hr for protein 
expression.  After incubating slides were fixed in 2% formaldehyde and incubated for 
1hr in primary antibody F1/T1/FL.  After incubation slides were washed 3X for 5 
minutes each in PBS.  Slides were then incubated for 1hr in secondary antibody 
normal mouse antibody conjugated to FITC in the dark. After incubation slides were 
then washed 3X PBS and once in water and mounted in Vectashield.  Slides were 
examined using fluorescence microscope for surface expression of PY1412 [Figure 
24]. 
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3.4. Immunofluorescence Assay  
 
 
                                   DAPI                    Fluorescence                      Merge                                                
   
Mouse 
Ab F1 
                                                           
   
Norma
l 
Mouse 
Ab 
Mouse 
Ab F1 
  
Mouse 
Ab F1 
Fig 23. Immunfluoresence localization of the PY1412 C-terminal Rhop-3 pDisplay recombinant.   
 
Formalin fixed slides were incubated in mAb or normal mouse antibody and FITC-goat-anti-mouse  
 
antibody.  C-terminalRhop-3 recombinant showing surface expression by immunofluorescence  
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using mAb F1 COS-7 cells Expressing C-terminal recombinant incubated in normal mouse  
 
antibody show no fluorescence.   
  
 
COS-7 cells expressing full-length Plasmodium falciaprumRhop-3 recombinant 
protein were examined for surface expression by IFA using a rabbit anti-Rhop-3 
antibody.  Expression was detected using the rabbit antibody and the normal mouse 
antibody showed some cross reactivity [Fig 24]. 
DAPI                                       Fluorescence                            Merge                                  
      
   
Rabbit 
Ab 686 
Normal 
Rabbit 
Ab 
01
Fig 24. Immunofluorescence images of expressed P. falciparum full-length Rhop-3 recombinant   
 
pDisplay/1-7, 44hr post transfection.  Immunfluoresence localization of the full-length Rhop-3  
 
pDisplay recombinant.  Formalin fixed slides were incubated in rAb or normal rabbit antibody and  
 
FITC-goat-anti-rabbit antibody. Full-length Rhop-3 recombinant showing expression by  
 
immunofluorescence using rAb #. COS-7 cells expressing full-length recombinant incubated in  
 
normal mouse antibody show some fluorescence.   
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COS-7 cells expressing the Plasmodium vivax PvDBPII protein were also detected by 
IFA. The protein is expressed as GFP fusion protein for easy detection in mammalian 
cells without the use of antibodies [Fig 25]. 
                    DAPI                    Fluorescence                            Merge                               
       
No Ab 
Fig 25. Immunofluorescence images of expressed Pv-DBPII SalI 44hr post transfection. .  
 
Immunfluoresence localization of the PvDBPIISal1 GFP control.  Formalin fixed slides were  
 
mounted in Vecta shield and examined under the microscope, expression of region II of Plasmodium  
 
vivax DBP. 
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COS-7 cells expressing Plasmodium falciparum Rhop-3 recombinant protein encoded 
by exons 1 to 3 were examined for surface expression by IFA using a rabbit anti-
Rhop-3 antibody.  Expression was detected using the rabbit antibody and the normal 
mouse antibody showed some cross reactivity [Fig 26]. 
                                 DAPI                          Fluorescence                            Merge                                     
   
Rabbit 
Ab #686 
               
Normal 
Rabbit 
Ab 
01
 
Figure 26. Immunofluorescence images of expressed P. falciparum pDisplay exon 1-3,44hr post  
 
transfection.   Immunfluoresence localization of the exon 1-3 Rhop-3 pDisplay recombinant.   
 
Formalin fixed slides were incubated in rAb or normal mouse antibody and FITC-goat-anti-rabbit  
 
antibody.  Partial Rhop-3 recombinant exon 1-3 showing expression by immunofluorescence using  
 
rAb #686. COS-7 cells exon 1-3 Rhop-3 recombinant incubated in normal rabbit antibody show  
 
some fluorescence.   
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COS-7 cells expressing Plasmodium falciparum Rhop-3 recombinant protein encoded  
by exon 7 were examined for surface expression by IFA using a rabbit anti-Rhop-3  
antibody.  Expression was detected using the rabbit antibody and the normal mouse  
antibody showed some cross reactivity [Fig 27]. 
                                 DAPI                       Fluorescence                            Merge                                        
                        
Rabbit 
Ab 
#686 
                        
Normal 
Rabbit 
Ab 
01
Figure 27. Immunofluorescence images of expressed P. falciparum pDisplay exon 7, 44hr post  
 
transfection.   Immunfluoresence localization of the exon 7 Rhop-3 pDisplay recombinant.   
 
Formalin fixed slides were incubated in rAb or normal mouse antibody and FITC-goat-anti-rabbit  
 
antibody.  Partial Rhop-3 recombinant exon 7 showing expression by immunofluorescence using  
 
rAb #686.  COS-7 cells exon 7 Rhop-3 recombinant incubated in normal rabbit antibody show no  
 
fluorescence.   
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CHAPTER IV 
 
DISCUSSION 
 
The malaria rhoptry protein Rhop-3 is an erythrocyte binding protein involved in the 
recognition and invasion of host cells by merozoites.  The C-terminus of Rhop-3 
generates immune responses in individuals living in malaria endemic regions and 
antibodies against the protein can inhibit red blood cell invasion in vitro.  The 110 
kDa Rhop-3 protein is encoded by a 7 exon gene, however the binding domain of the 
protein has not yet been reported.  The purpose of this study was to identify the 
binding domain of the Rhop-3 protein.  Different regions of P. falciparum Rhop-3 
and the C-terminus from of Rhop-3 from the rodent malaria parasite P. yoelii were 
expressed on the surface of COS-7 cells and subsequent erythrocyte binding assays 
(EBAs) carried out to examine the degree of binding.   
     Using cDNA from P. falciparum the full-length Rhop-3 gene (2.7 kb) pDIS-PF17, 
regions I-III (exon 1–3, 1.1 kb) pDIS-PF13, and region VI (exon 7, 0.6 kb) pDIS-PF7 
were cloned into the vector pDisplay.  PDIS-PY1412 encoding a protein in the C-
terminus from Rhop-3 (~1 kb) also cloned into the vector pDisplay.  To test 
recombinant protein binding to erythrocytes the purified clones were transfected into 
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COS-7 cells and recombinant proteins expressed on the surface of the COS cells.  
Erythrocyte binding assays were carried out using mouse and human cells and the 
cells checked for rosetting.  Region II of the P. vivax Duffy Binding Protein (DBPII) 
which binds to Duffy positive human RBC was used as a control for binding.  The 
transfection efficiency of COS-7 cells was determined by immunofluorescence 
assays. 
       In these experiments, it was shown that the recombinant clones expressed the 
proteins of interest on the surface of the COS cells.  Using rabbit antibody #686, 
which recognizes the  P. falciparum Rhop-3 protein, I was able to show that pDIS-
PF17, pDIS-PF13 and pDIS-PF7 were expressed on the surface of the COS cells.  
The recombinant P. falciparum Rhop-3 proteins did not bind to human or mouse 
RBCs 
Using mouse antibody F1, which recognizes the P. yoelii Rhop-3 protein I was able to 
show that pDIS-PY1412 was expressed on the surface of the COS cells.  In the EBAs 
pDIS-PY1412 bound to mouse erythrocytes but not to human erythrocytes.  A very 
high level of binding was seen in one independent EBA experiment, however 
attempts to reproduce the binding in other independent assays was not successful.   
Erythrocyte invasion by merozoite is dependent on binding of parasite proteins to 
receptors on the RBCs [Adams et al., 1992].  Antibodies directed against erythrocyte 
binding proteins may block erythrocyte invasion making such ligands attractive 
candidates for malaria vaccines [Pandey et al., 2002].   
  A small number of malaria proteins have been extensively studied for their binding 
properties using the COS-7 system, mainly P. falciparum EBA-175 [Sim et al., 1994] 
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P. vivax Duffy Binding Protein [Chitnis & Miller 1994, Adams et al., 1992, Michon 
et al., 2001, VanBurskirk et al., 2004] and P. yoelii AMA-1[Fraser et al., 2001].   
     An important aspect of the COS-7 system binding system is that the vector used 
enables surface expression of the parasite proteins of interest. The first vector used to 
express malaria protein to the surface of COS cells was an engineered vector pRE4 
[Cohen et al.1988].   Plasmid pRE4 contains the coding sequence gD-1and the Rous 
sarcoma virus promoter was designed to subclone the gD gene a virion envelope 
glycoprotein of herpes simples virus (HSV).  Mutations were made in the gD-1 gene 
and the proteins expressed in mammalian cells to study the effects of mutations on 
expression of gD [Cohen et al., 1988].  From these studies they found that synthesis 
of gD-1 was sensitive to changes involving cysteine residues.  pRE4 HSV gD has a 
25 amino acid signal peptide and a 24 amino acid hydrophobic transmembrane region 
which targets proteins to the  surface of mammalian cells.  pRE4 (provided by Drs. 
Gary Cohen and Roselyn Eisenberg, University of Pennsylvania, Philadelphia, PA) 
has been the main vector of choice used to target different regions of malaria parasite 
proteins to COS-7 cells to study binding. At the beginning of my project I obtained 
the pRE4 vector from Dr. Cohen, however I was not able to use it to construct any of 
clones due to poor amplification of the vector. 
     Using the pRE4 vector the binding domain of a P. vivax and P. knowlesi 
erythrocyte binding ligand was identified to lie within region II of these proteins 
[Chitnis & Miller 1994].  For each protein different regions of the protein were 
targeted to the surface of COS cells and binding assays performed to identify which 
expressed proteins also showed rosetting to human RBC’s.  The P. vivax DBP protein 
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binds only to human erythrocytes expressing the Duffy group antigen.   Using the 
same vector the binding domain of P. falciparum EBA-175 was identified as region 
II, a region containing a cysteine-rich motif and requirement for glycophorin A and 
sialic acid for erythrocyte recognition [Sim et al., 1994].  The P. yoelii AMA-1 
erythrocyte binding domain was also identified using the pRE4 vector, region 1/2 
mediated binding to mouse and rat erythrocytes but not human erythrocytes [Fraser et 
al., 2001].   
     The pRE4 vector has been effective in targeting different portions of malaria 
ligands to the surface of COS-7 cells to study binding, however, having a 
commercially available vector with the ability to target malaria proteins to the surface 
of mammalian cells would be more beneficial to researchers interested in studying 
binding. 
     Another designed vector which has been used to study erythrocyte binding 
proteins is HSVgD1/DBPII plasmid pEGFP-N1 (Clontech) which has been 
engineered to express the chimeric protein as a recombinant fusion at the N-terminus 
of green fluorescent protein (GFP). The HSVgD1-DBP was amplified from a pRE4-
DBPII construct and inserted into the appropriate site of the pEGFP-N1 vector. This 
designed construct pEGFP-DBPII has been used to further study the P. vivax DBP 
[Michon et al., 2000, Michon et al., 2001, VanBuskirk et al., 2004]. 
Besides Plasmodium yoelii AMA-1 [Fraser et al. 2001] the binding properties of 
rodent Plasmodium rhoptry proteins have not been investigated to show that a 
commercially available vector can also be successfully used to target proteins to the 
surface of mammalian cells to study erythrocyte binding. pDisplay has been used to 
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target other proteins such as hepatitis C virus envelope E2 protein [Forns et al.1999] 
and endoglin [Guerrero-Esteo et al. 2002] to the cell surface but has not been used to 
express malaria binding proteins. 
     Along with using the COS system erythrocyte binging activity has also been 
studied by means of using parasite culture supernatant, recombinant proteins and 
peptides.  The two-stage binding of the P. falciparum EBA-175 antigen was 
identified using parasite labeled culture supernatant [Kain et al.1993].  In these assays 
uninfected erythrocytes were incubated with culture supernatant and bound proteins 
eluted with a high salt buffer.  Erythrocytes can also be pre-treated with enzymes to 
study erythrocyte surface receptors required for protein recognition to facilitate 
binding.  The binding properties of P. falciparum EBA-175 has also been extensively 
studied using peptides [Jakobsen et al., 1998, Sim et al., 1990] and recombinant 
proteins [Pandey et al., 2002].  Erythrocyte binding assays using peptides are useful 
in identifying specific sequence residues within known binding domains that are 
sufficient for binding.   
     The binding properties of P. falciparum AMA-1 has been studied using synthetic 
peptides [Urquiza et al.2001, Valbuena et al.2006], RAP-1 [Patarroyo et al. 2006] an 
extensively studied Plasmodium vivax rodent rhoptry protein and RAP-2 [Patarroyo 
et al. 2004] have been studied using synthetic peptides.  Another extensively studied 
protein are the MSP proteins, MSP-1 has been the most characterized MSP protein. 
These proteins are involved in the initial interaction of the merozoite with erythrocyte 
receptors during invasion [Blackman et al.1991].  The binding properties of MSP 
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proteins have also been extensively studied using synthetic peptides [Patarroyo et al. 
2005, Patarroyo et al.2006, Patarroyo et al.2007]. 
     Erythrocyte binding assays using the COS system take a molecular approach to 
studying parasite ligand interaction with erythrocytes, this method can also be used to 
screen erythrocyte binding proteins that may be potential candidates for malaria 
vaccines.   
     The Plasmodium falciparum is highly (A + T) which makes it extremely difficult 
to express and maintain clones in Escherichia coli.   The overall (A+T) composition 
of P.falciparum is 80.6% an up to ~ 90% in introns [Gardner et al. 2002]  From my 
studies it is seen that, despite the great difficulty with working with an AT-rich 
genome of Plasmodium falciparum, it is possible to construct a full-length Rhop-3 
recombinant protein.  How stable the expressed protein is has not yet been determined 
but from IFA’s there is expression. Mouse RBC bound to COS-7 cells expressing the 
PY1412 protein following transfection and binding assay using a fresh batch cloned 
DNA. Due to the (A+T) rich genome is frequent rearrangements of Plasmodium 
genes when expressed in different hosts causing those genes to not always be stable.  
Rearrangements in P. yoelii can cause the genes to be even less stable as its genome 
is even more AT rich than that of P. falciparum. This would give an account for the 
variability in binding seen with the P. yoelii P1412 recombinant protein.    
     The conditions used for the transfection and binding assays were modified to see if 
the binding results obtained with pDIS-PY1412 could be reproduced, however these 
were not done with fresh cloned DNA.  These modifications included: (1) different 
incubation times for protein expression: 24hr, 42hr, 44hr, 48hr and up 60 72hrs (2) 
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length of time incubated in transfection media: 4 hr and 24hr (3) transfection reagent: 
Lipofectamine, Lipofectin, Lipofectamine with Plus reagent and Lipofectin with Plus 
reagent (4) incubation time with RBCs: 2hr, 4hr, 6hr and overnight. (5) temperature 
for incubation with RBCs: RT and  37°C for 2hr, 4hr and overnight.  One of my 
limitations during this study was available human red blood cells expressing the 
Duffy Blood group antigen to use with the PvDBPII positive control.  Due to this, 
binding using the Pv-DBPII was not consistent suggesting that there were times which 
the blood obtained from Interstate Blood Bank may have contained erythrocytes not 
expressing the Duffy Blood group antigen. The Duffy antigen is not routinely 
checked for by the blood bank during the processing procedure.  
     Findings from the current studies and others using rodent rhoptry proteins will be 
of benefit to the investigation of other rhoptry proteins that may be involved in 
erythrocyte recognition and invasion.  Due to the inconsistent binding obtained with 
PY1412 the binding conditions in future binding assays can be performed using other 
fragments within the C-terminus of the Rhop-3 protein.  IFA results showed that the 
PY1412 protein was expressed on the cell surface however the epitope recognized by 
the Rhop-3 antibodies may not be the same epitopes recognized by receptors on the 
RBCs.  This suggests that the inconsistency in binding may be a due to the 
conformation of the expressed protein and the availability of the epitope necessary for 
recognition by receptors on the erythrocytes. These studies can be to identify the 
specific sequence residues that are sufficient for binding.  The specificity of Rhop-3 
binding can be determined by using antibodies to see if this binding can be inhibited.   
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